Table 1.
Clinical and demographic characteristics of included patients.
| Drop-Out Group | NR | PR | R | p-Value | ||
|---|---|---|---|---|---|---|
|
N (%)
Tot = 195 |
28 (14.4) |
30 (15.4) |
35 (17.9) |
102 (52.3) | - | |
| N (%) MOH at Baseline | 23 (82.1) | 25 (83.3) | 29 (82.9) | 87 (85.3) | - | |
| N (%) MOH at Phase 1 | - | 26 (86.7) | 17 (48.9) | 11 (10.8) | ||
| N (%) MOH at Phase 2 | - | - | 15 (42.9) | 9 (8.8) | ||
| Gender (F/M) | 26/2 | 24/6 | 21/14 | 89/13 | <0.001 | |
| Age | 49.5 ± 9.7 | 45.4 ± 13.7 | 47.0± 12.0 | 47.8 ± 14.2 | 0.679 | |
| Headache days/month | Baseline | 22.1 ± 6.6 | 23.7 ± 5.4 | 23.8 ± 5.8 | 24.2 ± 5.6 | 0.375 |
| Phase 1 | - | 22.7 ± 6.7 ϕϕϕ | 17.4 ± 5.3 §§§ | 7.0 ± 4.3 §§§ | <0.001 | |
| Phase 2 | - | - | 15.3 ± 7.6 *** | 6.9 ± 5.1 *** | <0.001 | |
NR: “non-responders”, patients with reduction in the number of headache days per month < 25%; PR: “partially responders”, patients with reduction in the number of days of headache per month < 50%, but ≥25%; R: “responders”, patients with reduction in the number of headache days per month ≥50); p-value column refers to a comparison between groups (drop-outs, NR, PR, R); ɸɸɸ p = ns intra-group comparison (NR between Baseline and the end of Phase 1; §§§: p < 0.001 intra-group comparison (R or PR) between Baseline and the end of Phase 1; ***: p = ns intra-group comparison (R or PR) between the end of Phase 1 and the end of Phase 2.